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Value of the data
 First detailed analysis of the prevalence of Clostridium perfringens and Clostridium difficile shedding
by small animals (dogs and cats) in the Madrid region (Spain).
 Detailed phenotypic and genetic data of recovered isolates is provided, which may be useful for
comparison in future epidemiological surveys.
 Given the recent emergence of antibiotic-resistant strains of C. difficle, information on the anti-
microbial susceptibility profiles of the isolates obtained in this survey may be particularly valuable.1. Data
The data shown in Section 1.1 of this article provide detailed information on the veterinary clinics
that participated in a recent survey of the prevalence of fecal shedding of Clostridium perfringens and
C. difficile by dogs and cats which was carried out in the Madrid region (Spain) [1]. Furthermore, the
demographic and clinical features of recruited animals are detailed in Section 1.2, and Section 1.3
provides extensive data on the genetic and phenotypic characteristics of recovered bacterial isolates.1.1. General data about participating clinics
An overview of the 17 veterinary clinics that participated in the study (hereafter referred to as
clinics A to Q) is provided in Table 1. Two clinics (L and P) did not return a questionnaire of general
data about their centre (see Section 2) and in two other cases (clinics H and K) the returned ques-
tionnaire was incomplete. Participating clinics were scattered within the Madrid region (14 were
located in the capital city, two in other municipalities within the metropolitan area and one in a rural
location) and varied widely in their year of opening (from 1981 to 2014), number of cases attended
per week (x7S.D.¼37.6718.7 and 16.5711 for dogs and cats, respectively), number of fecal cultures
requested per week (1.672.4 and 0.971.8), and other parameters (Table 1). These clinics also dif-
fered in the antibiotics used for the treatment of diarrhea, but 12 of them (80% for which pharma-
cological data were available) reported the use of metronidazole for the treatment of these conditions.
Only three clinics (20%; F, J and O) acknowledged frequent request of microbiological culturing for
anaerobes, and five clinics (33.3%; D, F, H, N and O) reported occasional suspicion of C. difficile and/or
C. perfringens involvement in severe cases of diarrhea.
Table 1
Overview of the characteristics of the veterinary clinics that participated in the study.a
Clinic Opening
year
No. cases per weekb No. diarrea cases per
weekb
No. fecal samples per
weekb
No. fecal cultures per
weekb
A 2014 61 (55 D, 6 C) 2.5 (2 D, 0.5 C) 1 (1 D) 0.5 (0.5 D)
B 1994 82 (50 D, 32 C) 2.5 (2 D, 0.5 C) 3.5 (3 D, 0.5 C) 0
C 2009 11 (10 D, 1 C) 5.5 (5 D, 0.5 C) 1 (1 D) 0
D 2014 40 (22 D, 18 C) 8 (7 D, 1 C) 7 (5 D, 2 C) 0
E 1993 40 (20 D, 20 C) 2 (2 D) 4 (2 D, 2 C) 4 (2 D, 2 C)
F 1981 100 (70 D, 30 C) 14 (10 D, 4 C) 2.3 (2 D, 0.3 C) 0.31 (0.3 D, 0.01 C)
G 1984 27.5 (16 D, 11.5 C) 11.5 (8 D, 3.5 C) 1.5 (1 D, 0.5 C) 1.5 (1 D, 0.5 C)
H 2002 55 (35 D, 20 C) 5 (4 D, 1 C) NA NA
I 1992 70 (60 D, 10 C) 8 (7 D, 1 C) 1.5 (1 D, 0.5 C) 0
J 2004 90 (48 D, 42 C) 12 (8 D, 4 C) 16 (10 D, 6 C) 14 (8 D, 6 C)
K 1985 NA NA 10 (6 D, 4 C) 10 (6 D, 4 C)
L NA NA NA NA NA
M 2001 47.5 (35 D, 12.5 C) 4.5 (4 D, 0.5 C) 4.5 (4 D, 0.5 C) 3 (2.5 D, 0.5 C)
N 1999 35 (25 D, 10 C) 4 (3 D, 1 C) 4 (3 D, 1 C) 1 (1 D)
O 2010 26 (20 D, 6 C) 3 (2.5 D, 0.5 C) 0.5 (0.5 D) 0.5 (0.5 D)
P NA NA NA NA NA
Q 2005 72 (60 D, 12 C) 20 (20 D) 2 (2 D) 0








a See also Fig. 1.
b D, dogs; C, cats. All figures refer to the last 12-month period.
c x7S.D.
Table 2
Overview of the animals that were recruited for this studya.
Clinic Nb Dogs Cats
n Sex ratioc Age distribution Days since last
episode of
diarrhea
n Sex ratioc Age distribution Days since last
episode of
diarrhea
o1 yr 1–6 yr Z7 yr 0 r30 430 o1 yr 1–6 yr Z7 yr 0 r30 430
A 6 6 2:1 33.3% 66.7% 0% 0% 66.7% 33.3% 0 – – – – – – –
B 15 12 1:5 25% 25% 50% 25% 0% 75% 3 2:1 0% 33.3% 66.7% 0% 0% 100%
C 8 4 3:1 50% 50% 0% 0% 25% 75% 4 1:1 0% 25% 75% 50% 0% 50%
D 3 2 1:1 0% 100% 0% 0% 0% 100% 1 0:1 0% 0% 100% 0% 0% 100%
E 4 3 2:1 0% 66.7% 33.3% 0% 66.7% 33.3% 1 0:1 0% 0% 100% 100% 0% 0%
F 12 5 2:3 0% 20% 80% 0% 40% 60% 7 4:3 14.3% 85.7% 0% 0% 0% 100%
G 17 15 11:4 20% 40% 40% 13.3% 26.7% 60% 2 0:1 0% 100% 0% 0% 0% 100%
H 5 5 4:1 100% 0% 0% 20% 20% 60% 0 – – – – – – –
I 6 5 4:1 20% 60% 20% 40% 20% 40% 1 1:0 0% 0% 100% 0% 100% 0%
J* 8 3 2:1 0% 66.7% 0% 33.3% 66.7% 0% 5 3:2 20% 60% 0% 40% 60% 0%
K 2 2 1:0 0% 50% 50% 0% 0% 100% 0 – – – – – – –
L* 2 2 0:1 0% 0% 50% 50% 0% 50% 0 – – – – – – –
M 27 22 4:7 4.5% 59.1% 36.4% 0% 13.6% 86.4% 5 3:2 20% 60% 20% 0% 0% 100%
N* 9 8 7:1 12.5% 37.5% 50% 12.5% 0% 37.5% 1 1:0 0% 0% 100% 0% 0% 100%
O 11 4 1:1 25% 75% 0% 0% 25% 75% 7 5:2 14.3% 57.1% 28.6% 0% 0% 100%
P 1 1 0:1 100% 0% 0% 100% 0% 0% 0 – – – – – – –
Q 6 6 5:1 16.7% 50% 33.3% 33.3% 33.3% 33.3% 0 – – – – – – –
Total* 142 105 59:46 20% 45.7% 32.4% 13.3% 21.9% 61% 37 21:16 10.8% 54.1% 32.4% 13.5% 10.8% 75.7%
a See also Fig. 1. Asterisks indicate that there were some recruited animals with missing data and thus the sum of
percentages can be o100%.
b Total number of animals that were recruited (i.e. dogs and cats).
c Number of males: number of females.
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Fig. 1. Characteristics of the animal populations recruited for this study. A) Bar plot showing the distribution of recruited
animals per species: dog, green bars; cats, orange bars. For each participating clinic (A to Q), the overall number of animals is
indicated between parentheses. B) Bar plot of the overall age distribution of dogs (n¼105; green bars) and cats (n¼37; orange
bars) recruited for the study. C) Pie charts of the overall sex distribution of dogs (n¼105) and cats (n¼37) included in the study.
Blue and pink sectors represent male (M) and female (F) subpopulations, respectively. D) Bar plot of the antimicrobial treat-
ments administered to recruited dogs and cats (green and orange bars, respectively) r30 days before sampling. E) Bar plot of
recent pharmacological treatments administered to recruited dogs and cats (green and orange bars, respectively) r30 days
before sampling. Abbreviations: ACE, angiotensin-converting-enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs; PPIs,
proton pump inhibitors. In panels D and E, pharmacological treatment data were not available for a total of 48 animals (32 dogs
and 16 cats).
S. Álvarez-Pérez et al. / Data in Brief 14 (2017) 88–100 911.2. Demographic and clinical features of recruited animals
The demographic characteristics of recruited animals are summarized in Table 2 and Figs. 1 and 2.
A total of 142 animals, including 105 dogs and 37 cats (73.9% and 26.1% of total, respectively; Fig. 1A)
of diverse breeds (Fig. 2), were recruited for the study. The male/female ratio of animals varied widely
Fig. 2. Bar plots showing the breed distribution of recruited dogs (n¼105, left panel) and cats (n¼37, right panel). *Other dog
breeds (n): Boxer (3), Setter (3), Shih Tzu (3), American Staffordshire Terrier (2), Belgian Shepherd (2), Border Collie (2), Chinese
Shar-Pei (2), Cocker Spaniel (2), Golden Retriever (2), Labrador Retriever (2), Pug (2), Shiba Inu (2), Andalusian Hound (1),
Chihuahua (1), Dalmatian (1), Galician Palleiro (1), Hound (1), Mastiff (1), Miniature Pinscher (1), Pit bull (1), Poodle (1), Water
dog (1).
S. Álvarez-Pérez et al. / Data in Brief 14 (2017) 88–10092among clinics, with the overall values for dogs and cats being similar (56.2%, 43.8% and 56.8%, 43.2%,
respectively; Fig. 1C). The age distribution of sampled animals also showed ample variation among
clinics, but the overall values were similar for the dog and cat subpopulations: 20%, 45.7%, 32.4% of
dogs and 10.8%, 54.1%, 32.4% of cats had o1 year, 1–6 years and Z7 years, respectively (Table 2).
The overall proportion of dogs and cats with diarrhea on the sampling date were very similar
(13.3% and 13.5%, respectively), and in both cases most animals had not suffered any episode of
diarrhea within the preceding 30 days (61% and 75.7%, respectively) (Table 2). Only 24.7% (18/73) of
dogs and 14.3% (3/21) of cats for which medication data was available were under antibiotic treat-
ment on the sampling date or within the previous 30 days, with metronidazole and amoxicillin
ranking first and second, respectively (Fig. 1D). Other pharmacological treatments of sampled animals
are shown in Fig. 1E.
The demographic data and clinical features of animals yielding positive fecal cultures for C. per-
fringens and/or C. difficile are detailed in Table 3 (see also Álvarez-Pérez et al. [1]).
1.3. Genetic and phenotypic characteristic of C. perfringens and C. difficile isolates
Table 3 includes an overview of the genetic and phenotypic characteristics of the bacterial isolates
obtained from recruited animals. Additionally, the toxinotypes, PCR ribotypes (only for C. difficile
isolates), amplified fragment length polymorphism (AFLP) genotypes and antimicrobial susceptibility
profiles of C. perfringens and C. difficile isolates are detailed in Tables 4 and 5, respectively.2. Experimental design, materials and methods
Our survey was performed during one week (from November 24 to December 1, 2015) in a total of
17 primary care veterinary clinics from the Madrid region (Spain). The staff of participating clinics
received training for data and sample collection, and email and telephonic support was available
throughout the duration of the study. Veterinarians of participating centers were asked to select two
swab samples of all feces shed by dogs and cats at their clinic, regardless of the age, origin and clinical
condition of the animals, and to send those samples to a central reference laboratory at the Faculty of
Veterinary Medicine of Complutense University of Madrid. Additionally, the staff of each participating
clinic had to complete a questionnaire of general data about the centre and a second questionnaire for
each pair of fecal swabs obtained requesting data on the sample (collection date, consistency of feces
and presence of blood) and the animal of origin (species, breed, sex, age, clinical status and episodes
of diarrhea and medication(s) within the previous 30 days). An informed consent and agreement to
participate in the study was obtained from the owners of each animal before enrolment. Animals
Table 3










resistances) of C. perfringens
isolatese
Genotype (antimicrobial
resistances) of C. difficile
isolatesf
A A/02 Dog, Mixed-
breed
5 F Routine analysis None No None p063, p064, p065 –
B B/02 Dog, Whippet 13 F Routine analysis Lymphoma No None p067 –
B/06 Dog, Whippet 7 F Routine analysis None No None p027, p028 [2 isolates] –
B/07 Dog,
Schnauzer
9 F Routine analysis None No None p011, p012, p023 –
B/08 Dog,
Schnauzer





o1 F Recent history
of Isospora
infection




6 F Routine analysis None No None p037 –
B/13 Cat, European
shorthair
9 F Routine analysis None No None p003 (MTZ), p006, p031 –
B/14 Cat, European
shorthair
1 M Routine analysis None No None p069, p072 –
D D/02 Dog, Hound 1 F Routine analysis None No None p087 (MTZ), p088 (LZD), p095 –




Heart failure Yes (5 d) Amoxicillin-
clavulanic
acid
NA RT?/d13 (CLI/ERY/PEN) [2
isolates], RT?/d14 (CLI/
ERY/PEN)
F F/09 Cat, Persian 6 M Routine analysis None No None p004, p005 –
G G/01 Dog, Labrador 12 M Routine analysis None Yes (7 d) Doxycycline p106 –
Follow-up
analysis
None No None p041, p092, p097 –
G/05 Dog, Boxer o1 M Routine analysis Food allergy No None p030 (MTZ), p050, p096 –
G/06 Cat, Persian 2 F Routine analysis None No None p026 –
H H/03 Dog, Mastiff o1 F Routine analysis None No None p078 (PEN), p102 (IPM, PEN),
p103
–
H/05 Dog, Pit bull o1 M Routine analysis None No None p008, p034, p079 (IPM, LZD,
PEN)
–

































resistances) of C. perfringens
isolatese
Genotype (antimicrobial




None No None p052 (LZD) –
J J/01 Dog,
Schnauzer
? F Routine analysis Food allergy Yes (10 d) None p053, p058 (ERY, LVX) –
J/03 Dog, Golden
Retriever
4 M Acute enteritis None Yes (0 d) None p013, p017, p018 –
J/07 Dog,? 1 M Routine analysis None Yes (8 d) None p101 –
K K/02 Dog, Poodle 10 M Routine analysis Heart murmur No None p089 –
M M/04 Dog, Giant
Schnauzer
11 F Routine analysis None Yes (30 d) None p090[2 isolates], p091 –
Follow-up
analysis
None Yes (5 d) None p043 (TET), p076 (TET), p077 –
M/06 Dog, Brittany 6 F Routine analysis Obesity No None p060, p061, p066 –
Follow-up
analysis
Obesity No None p068, p070 (TET), p104 –
M/07 Dog, Brittany 3 F Entetitis Recent Toxocara canis
infection, obesity
Yes (25 d) None p081 –
Follow-up
analysis
Obesity No None p033, p042 (TET), p056 –
M/08 Dog, Mixed
Hound
3 F Routine analysis None No None p040, p062, p080 –
M/13 Cat, European
shorthair
4 F Routine analysis None No None p025, p029, p071 –
M/14 Dog, Mixed-
breed
8 F Routine analysis Recent removal of mam-
mary tumor





None No None p014[2 isolates], p015 –
M/23 Dog, Yorkshire
Terrier
12 F Routine analysis Frequent pseudo-preg-
nancies, benign mammary
tumors
No None p032 –
M/25 Dog, German
Shepherd
5 F Routine analysis Obesity No None p001 (TET), p057 –
Follow-up
analysis





















Seizure disorder No None p086 (MTZ), p093, p100 –
N N/01 Dog, Mixed
Shih Tzu
1 M Routine analysis None No None p044, p045, p046 –
N/
12&14g











O O/04 Cat, European
shorthair
4 M Routine analysis None No None p094 –
O/11 Dog, Border
Collie
2 M Routine analysis None Yes (7 d) None p007, p009, p010 –
Q Q/03 Dog, Maltese 7 M Routine analysis Frequent gastrointestinal
problems, heart disease




2 M Allergic colitis Frequent gastrointestinal
problems





None No None p022, p098 –
Q/05 Dog,
Dachshund
14 M Routine analysis None No None p048, p049 –
a Recruited animals were designated by a capital letter (corresponding to the clinic of origin) followed by a virgule and consecutive numbers.
b ?: Missing data.
c No: no diarrhea episodes were reported within the previous 30 days. For positive responses, the number of days since the last episode of diarrhea is indicated between par-
entheses.
d Antibiotic treatment(s) administered within the previous 30 days. For an overview of other pharmacological treatments see Fig. 1E.
e AFLP genotypes were arbitrarily designated by a lower case ‘p’ followed by a number (see Table 4). In vitro resistance to benzylpenicillin (PEN), erythromycin (ERY), imipenem (IPM),
levofloxacin (LVX), linezolid (LZD), metronidazole (MTZ) and/or tetracycline (TET) is indicated between parentheses. The number of isolates belonging to each strain type (when different to
one) is shown between square brackets. Dashes mean that C. perfringens was not isolated from the corresponding animal. NA: not analyzed (a single fecal swab was available for some
animals, and this was used for C. difficile testing).
f In this case, ribotype (RT) and AFLP fingerprinting information is included. AFLP genotypes were arbitrarily designated by a lower case ‘d’ followed by a number (see Table 5). In vitro
resistance to benzylpenicillin (PEN), clindamycin (CLI) and/or erythromycin (ERY) is indicated between parentheses. Additionally, all C. difficile isolates displayed resistance to levofloxacin
and imipenem. The number of isolates belonging to each strain type (when different to one) is shown between square brackets. RT?: unknown ribotype. Dashes mean that C. difficile was
not isolated from the corresponding animal.















Characteristics of the Clostridium perfringens isolates obtained in the study.
Isolatea Toxinotypeb AFLP genotypec Antibiotic susceptibility (MIC, µg/ml)d
AMC CLI ERY IPM LVX LZD MTZ PEN RIF TEC TET TGC VAN
A/02P1 A (cpe, cpb2*) p063 0.125 0.25 2 0.064 0.5 4 16 0.5 0.008 0.064 8 1 1
A/02P2 A (cpb2*) p064 0.032 0.032 0.064 0.064 0.25 0.125 8 0.125 0.004 0.032 4 0.125 0.5
A/02P3 A (cpe) p065 0.032 0.032 0.032 0.064 0.25 0.125 8 0.064 0.002 0.032 0.125 0.064 0.5
B/02P1 A p067 0.032 0.064 2 0.064 0.25 4 16 0.064 0.008 o0.016 0.125 0.064 0.5
B/06P1 A (cpb2*) p027 0.064 0.064 2 0.064 0.25 4 16 0.032 0.004 o0.016 4 0.25 0.5
B/06P2 A (cpb2*) p028 0.032 0.125 2 0.5 0.25 4 16 0.125 0.004 0.032 4 0.5 0.5
B/06P3 A (cpb2*) p028 o0.016 0.5 2 0.5 0.25 4 16 0.064 0.008 0.032 4 0.5 0.5
B/07P1 A (cpe) p011 0.032 0.125 1 0.032 0.25 4 16 0.032 0.004 o0.016 2 0.125 0.25
B/07P2 A (cpe) p012 0.032 0.125 2 0.064 0.25 4 16 0.064 0.008 0.032 4 0.125 0.25
B/07P3 A (cpe) p023 o0.016 0.125 2 0.064 0.25 2 16 0.125 0.008 0.032 4 0.125 0.25
B/08P1 A (cpb2*) p047 0.032 0.064 2 0.125 0.25 4 16 0.064 0.004 o0.016 4 0.125 0.5
B/08P2 A (cpb2*) p002 0.032 0.25 2 0.064 0.25 2 16 0.064 0.008 0.032 2 0.5 0.5
B/08P3 A (cpb2*) p051 0.016 0.125 2 0.125 0.25 4 16 0.064 0.008 0.032 4 0.25 0.5
B/11P1 A (cpb2*) p035 0.125 0.016 1 0.064 0.25 1 16 0.125 0.004 o0.016 4 0.125 0.5
B/11P2 A (cpb2*) p036 0.016 0.25 2 0.064 0.25 2 8 0.125 0.004 0.016 4 0.5 0.5
B/11P3 A (cpb2*) p036 0.032 0.25 2 0.008 0.5 2 16 0.125 0.004 0.032 4 0.5 0.5
B/12P1 A p037 0.032 0.016 0.125 0.064 0.25 1 8 0.032 0.004 o0.016 1 0.125 0.5
B/13P1 A (cpb2*) p003 0.064 0.064 2 0.032 0.5 4 32 (R) 0.064 0.008 0.032 2 0.064 0.5
B/13P2 A p006 0.032 0.064 2 0.25 0.5 4 16 0.125 0.004 0.064 8 0.125 0.5
B/13P3 A p031 0.064 0.25 2 0.064 0.25 4 16 0.125 0.008 o0.016 8 0.125 0.5
B/14P1 A p069 0.064 0.125 2 0.064 0.5 2 16 0.25 0.008 0.032 4 0.25 0.5
B/14P2 A p072 0.032 2 2 0.032 0.25 o0.016 8 0.064 0.004 o0.016 4 0.25 0.5
D/02P1 E (cpe) p087 0.064 o0.016 1 0.5 0.25 2 32 (R) 0.064 0.002 0.032 4 0.064 0.5
D/02P2 E (cpe) p088 0.064 0.064 4 0.125 0.25 8 (R) 8 0.125 0.004 0.032 4 0.25 1
D/02P3 E (cpe) p095 0.032 0.032 1 0.064 0.5 1 16 0.125 0.004 0.032 2 0.25 0.5
F/09P2 A p004 0.125 0.064 0.5 0.25 0.25 0.5 8 0.25 0.004 0.032 0.125 0.064 0.5
F/09P3 A p005 0.064 0.064 2 1 0.25 4 8 0.25 0.008 0.064 4 0.064 1
G/01P1 A p105 0.064 0.064 0.064 0.064 0.5 1 16 0.064 0.004 o0.016 1 0.125 0.5
G2/01P1† A (cpb2*) p092 0.064 0.064 4 0.125 0.25 4 8 0.125 0.008 0.064 4 0.25 0.5
G2/01P2† A (cpb2*) p097 0.064 o0.016 0.064 0.125 0.25 4 16 0.125 0.008 0.016 4 0.064 0.5
G2/01P3† A (cpb2*) p041 0.032 0.125 2 0.064 0.25 4 8 0.125 0.004 0.016 8 0.25 0.5
G/05P1 A (cpb2*) p030 0.125 0.064 2 0.064 0.25 4 32 (R) 0.125 0.008 0.032 8 0.125 0.5
G/05P2 A (cpb2*) p050 0.064 0.25 1 0.064 0.25 2 8 0.5 0.004 o0.016 4 0.25 0.5
G/05P3 A p096 o0.016 0.125 1 0.032 0.5 4 4 0.125 0.004 o0.016 4 0.125 0.5
G/06P1 A p026 0.125 0.125 2 0.064 0.5 4 16 0.125 0.008 0.032 8 0.25 1
H/03P1 A p102 8 0.125 2 Z32 (R) 0.25 4 16 8 (R) 0.004 0.032 8 0.125 0.5














H/03P3 A p103 0.032 0.064 1 0.125 2 2 8 0.064 0.004 0.064 8 0.5 0.5
H/05P1 A p079 8 0.125 2 Z32 (R) 0.25 8 (R) 16 8 (R) 0.004 0.032 8 0.5 0.5
H/05P2 A p008 0.032 0.125 1 0.064 0.25 1 4 0.064 0.002 0.016 4 0.125 0.5
H/05P3 A p034 o0.016 0.064 2 0.125 0.25 4 16 0.032 0.008 0.032 4 0.125 0.5
I/02P1 A p054 0.064 0.064 2 0.125 0.25 2 16 0.125 0.004 0.016 4 0.125 0.5
I/02P2 A p055 0.032 o0.016 4 0.064 0.5 0.25 16 0.064 o0.002 o0.016 4 0.064 0.5
I/04P1 A (cpe) P099 0.125 0.032 0.25 0.125 0.25 1 16 0.125 0.004 0.032 0.125 0.032 0.5
I/04P2 A p082 0.032 0.25 2 0.032 0.25 0.5 16 0.125 o0.002 o0.016 4 0.125 0.5
I2/04P1† A (cpe) p052 0.032 0.125 2 0.064 0.25 8 (R) 16 0.125 0.008 0.032 4 0.25 0.5
J/01P1 A (cpb2*) p053 0.064 0.125 2 0.064 0.5 4 16 0.125 0.008 0.032 8 0.5 1
J/01P2 A (cpb2*) p058 0.064 0.25 32 (R) 0.125 Z32 (R) 2 16 0.125 0.008 0.032 4 0.125 0.5
J/03P1 A p018 0.064 0.032 2 0.064 0.5 4 16 0.064 0.004 o0.016 0.125 0.064 0.5
J/03P2 A (cpb2*) p013 0.125 0.032 0.125 0.064 0.25 4 16 0.064 o0.002 2 1 0.032 2
J/03P3 A (cpb2*) p017 0.016 0.032 0.125 0.032 0.25 2 16 0.064 0.004 o0.016 2 0.032 0.5
J/07P1 A (cpb2) p101 0.016 o0.016 0.125 0.064 0.25 1 16 0.032 0.008 0.032 0.125 0.032 0.5
K/02P1 A p089 0.032 0.125 2 0.5 0.25 4 16 0.125 0.004 0.032 4 0.125 0.5
M/04P1 A (cpe) p090 0.064 0.125 2 0.064 0.25 4 16 0.125 0.008 0.064 8 0.5 0.5
M/04P2 A (cpe) p090 0.032 0.125 2 1 0.5 4 16 0.064 0.004 0.064 4 0.5 0.5
M/04P3 A (cpe) p091 0.032 o0.016 o0.016 0.5 0.25 4 16 0.064 0.016 0.064 4 0.125 0.5
M2/04P1† A (cpb2*) p043 0.032 0.032 2 0.25 0.25 4 16 0.032 0.004 0.016 16 (R) 1 0.5
M2/04P2† A (cpb2*) p076 0.032 0.064 2 0.5 0.25 4 8 0.064 0.008 0.016 16 (R) 0.5 0.5
M2/04P3† A (cpb2*) p077 0.032 0.032 0.064 0.064 0.5 2 8 0.064 0.004 0.016 4 0.25 0.5
M/06P1 A (cpb2*) p066 0.125 0.064 2 0.064 0.25 4 16 0.5 0.008 0.064 8 2 1
M/06P2 A (cpb2*) p060 0.032 0.064 1 0.064 0.25 2 16 0.125 0.004 0.032 4 0.25 0.5
M/06P3 A (cpe, cpb2*) p061 0.032 0.032 0.5 0.125 0.25 4 16 0.125 0.004 0.032 4 0.125 0.5
M2/06P1† A p068 0.064 0.064 2 0.5 0.5 4 16 0.25 0.008 0.032 8 0.125 0.5
M2/06P2† A p070 0.016 0.125 2 0.032 0.25 4 16 0.125 0.004 0.032 16 (R) 0.5 0.5
M2/06P3† A p104 0.064 0.032 0.25 0.125 0.25 4 8 0.125 0.008 0.016 4 0.5 0.5
M/07P1 A p081 0.25 0.032 2 0.125 0.25 4 8 1 0.008 0.032 4 0.5 0.5
M2/07P1† A (cpb2*) p042 o0.016 0.032 2 0.064 0.25 4 16 0.125 0.008 0.016 16 (R) 1 0.5
M2/07P2† A p056 0.032 0.064 4 0.125 0.25 4 8 0.125 0.004 0.032 4 0.25 0.5
M2/07P3† A p033 0.032 0.064 1 0.125 0.5 4 8 0.25 0.008 0.032 8 0.25 0.5
M/08P1 A (cpb2*) p062 0.064 0.5 2 0.064 0.25 4 16 0.25 o0.002 0.032 8 2 0.5
M/08P2 A p040 0.032 0.064 0.25 0.064 0.25 4 16 0.125 0.008 0.016 1 0.064 0.5
M/08P3 A p080 0.032 o0.016 0.032 0.064 0.5 1 8 0.064 o0.002 0.032 4 0.125 0.5
M/13P1 A (cpb2*) p029 0.125 0.25 2 0.064 0.25 4 16 0.064 0.004 0.032 8 4 1
M/13P2 A (cpb2*) p025 0.032 0.032 0.032 0.032 0.25 0.125 8 0.064 o0.002 0.032 4 0.032 0.5
M/13P3 A (cpe) p071 0.032 1 2 0.125 0.5 2 8 0.064 0.002 0.032 4 0.125 0.5
M/14P1 A (cpe) p016 0.016 0.064 2 0.064 0.25 4 8 0.064 0.004 0.016 0.125 0.064 0.5
M/14P2 A (cpe) p020 0.125 0.5 2 0.064 0.25 2 4 0.125 0.004 o0.016 2 0.032 0.5
M/14P3 A (cpe) p021 0.032 0.125 2 0.032 0.25 2 8 0.064 0.008 0.016 4 0.125 0.5
M2/14P1† A (cpb2*) p014 o0.016 0.032 2 0.125 0.25 1 8 0.064 o0.002 0.016 4 0.125 0.5
M2/14P2† A (cpb2*) p015 0.064 0.032 0.032 0.064 0.25 2 16 0.064 0.004 0.016 4 0.5 0.5














Table 4 (continued )
Isolatea Toxinotypeb AFLP genotypec Antibiotic susceptibility (MIC, µg/ml)d
AMC CLI ERY IPM LVX LZD MTZ PEN RIF TEC TET TGC VAN
M/23P1 A (cpb2) p032 0.064 0.25 2 0.016 0.25 2 16 0.25 0.008 0.032 4 0.125 1
M/25P1 A p001 0.125 2 4 0.064 0.5 4 16 0.25 0.008 0.125 16 (R) 2 1
M/25P2 A p057 0.032 0.016 2 0.064 0.25 2 8 0.032 0.002 0.064 8 0.125 0.5
M2/25P1† A p083 0.032 0.125 2 0.064 0.5 4 8 0.125 0.004 0.064 16 (R) 1 0.5
M2/25P2† A p084 0.032 0.125 2 0.125 0.25 8 (R) 8 0.125 0.008 0.032 16 (R) 2 0.5
M2/25P3† A p085 0.032 0.125 2 0.125 0.25 8 (R) 8 0.125 0.004 0.032 16 (R) 1 0.5
M/26P1 A p039 0.125 0.125 4 0.064 0.25 4 16 0.25 0.004 0.032 8 0.25 1
M/26P2 A p038 0.032 o0.016 1 0.064 0.25 2 8 0.064 0.002 0.016 8 0.064 0.5
M2/26P1† A p100 0.032 0.032 2 1 0.25 4 16 0.125 0.004 0.032 4 0.25 0.5
M2/26P2† A p086 0.016 0.064 2 0.125 0.5 4 32 (R) 0.125 0.008 0.032 2 0.125 0.5
M2/26P3† A (cpb2*) p093 0.016 0.064 2 0.5 0.5 4 8 0.064 0.004 0.032 4 0.25 0.5
N/01P1 A (cpb2*) p044 0.125 0.125 2 0.064 0.25 4 16 0.064 0.004 o0.016 8 0.25 1
N/01P2 A (cpb2*) p045 0.032 0.064 2 0.064 0.5 4 16 0.25 0.004 0.064 8 0.5 0.5
N/01P3 A (cpb2*) p046 0.032 0.125 4 0.064 0.5 1 8 0.125 0.004 o0.016 8 0.25 0.5
N/12P1 A (cpe) p024 0.064 0.064 2 0.125 0.25 4 16 0.064 0.008 0.032 4 0.5 0.5
N/14P1 A p019 0.032 0.032 0.25 0.125 0.25 2 8 0.032 0.004 o0.016 4 0.125 0.5
O/04P1 A p094 0.125 0.064 2 0.25 0.25 4 16 1 0.008 0.032 4 0.125 0.5
O/11P1 A (cpb2*) p007 0.064 o0.016 0.064 0.064 0.25 4 8 0.125 o0.002 0.016 4 0.125 0.5
O/11P2 A p009 0.032 0.064 1 0.032 0.25 1 8 0.032 0.004 0.032 8 0.125 0.5
O/11P3 A p010 0.032 0.064 2 0.064 0.25 2 8 0.064 0.004 0.032 8 0.125 0.5
Q/03P1 A p073 0.125 0.016 2 0.064 0.25 4 32 (R) 0.064 0.004 o0.016 4 0.125 0.5
Q/03P2 A p075 0.064 0.032 2 0.125 0.25 8 (R) 8 0.25 0.008 0.032 4 0.125 0.5
Q/03P3 A p074 0.032 0.125 2 0.125 0.25 4 16 0.125 0.008 0.032 4 0.25 0.5
Q/04P2 A p059 0.032 0.125 2 0.125 0.25 4 16 0.125 0.004 0.016 4 0.125 0.5
Q2/04P1† A (cpb2*) p022 o0.016 0.125 2 0.064 0.25 4 16 0.125 0.004 0.016 4 0.25 0.5
Q2/04P3† A p098 0.032 0.016 4 0.064 0.25 4 16 0.125 0.004 0.032 2 0.125 0.5
Q/05P1 A (cpb2*) p048 0.016 o0.016 0.25 0.064 0.5 1 16 0.016 o0.002 o0.016 1 0.125 0.5
Q/05P2 A (cpb2*) p049 o0.016 0.125 2 0.064 0.5 2 16 0.25 0.004 0.016 4 0.125 0.5
a Isolates whose names only differ in the last number were retrieved from the same animal (e.g. H/05P1, H/05P2 and H/05P3; see Table 3). Daggers (and the number 2 after the clinic's
code) indicate isolates that were obtained in the follow-up analysis.
b cpe: possession of the gene encoding for enterotoxin. cpb2: possession of the gene encoding for β2 toxin, with asterisks indicating atypical forms of the gene (as determined by PCR
amplification).
c According to the UPGMA dendrogram shown in Fig. 1 of Álvarez-Pérez et al. [1].
d Minimum inhibitory concentration (MIC). AMC, amoxicillin/clavulanic acid; CLI, clindamycin; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MTZ,















Characteristics of the Clostridium difficile isolates obtained in the study.
Isolatea PCR ribotypeb AFLP genotypec Antibiotic susceptibility (MIC, µg/ml)d
AMC CLI ERY IPM LVX LZD MTZ PEN RIF TEC TET TGC VAN
B/08D1 RT154 d06 1 0.125 0.25 Z32 (R) Z32 (R) 0.25 0.064 Z32 (R) o0.002 0.064 0.032 0.016 0.25
B/08D2 RT154 d07 0.25 0.064 0.25 Z32 (R) Z32 (R) 0.25 0.032 2 (R) o0.002 0.032 0.032 0.032 0.125
B/08D3 RT154 d05 0.125 0.032 0.064 Z32 (R) Z32 (R) 0.125 0.032 32 (R) o0.002 0.064 o0.016 o0.016 0.125
E/03D1 RT? d13 0.5 Z256 (R) Z256 (R) Z32 (R) Z32 (R) 1 0.032 Z32 (R) o0.002 0.064 0.5 o0.016 0.125
E/03D2 RT? d13 0.25 Z256 (R) Z256 (R) Z32 (R) Z32 (R) 0.5 0.064 Z32 (R) 0.004 0.032 1 0.032 0.125
E/03D3 RT? d14 0.5 Z256 (R) Z256 (R) Z32 (R) Z32 (R) 1 0.125 Z32 (R) o0.002 0.032 0.5 0.032 0.125
M/14D1 RT106 d15 0.5 0.064 0.125 Z32 (R) Z32 (R) 0.25 0.064 Z32 (R) o0.002 0.032 o0.016 o0.016 0.125
M/14D2 RT106 d01 0.25 0.25 1 Z32 (R) Z32 (R) 0.125 0.064 4 (R) 0.004 0.032 o0.016 o0.016 0.25
M/14D3 RT106 d03 0.5 0.125 0.25 Z32 (R) Z32 (R) 0.5 0.125 2 (R) o0.002 0.032 0.032 o0.016 0.125
N/19D1 RT009-like d08 0.5 0.064 0.25 Z32 (R) Z32 (R) 0.5 0.032 4 (R) o0.002 0.064 0.032 o0.016 0.25
N/19D2 RT009-like d04 0.064 o0.016 0.016 Z32 (R) Z32 (R) 0.064 o0.016 1 o0.002 0.032 o0.016 o0.016 0.125
N/19D3 RT009-like d09 0.25 o0.016 0.064 Z32 (R) Z32 (R) 0.125 o0.016 4 (R) o0.002 0.032 0.032 o0.016 0.125
N/20D1 RT009-like d10 0.25 0.064 0.125 Z32 (R) Z32 (R) 0.25 0.032 Z32 (R) o0.002 0.032 0.032 o0.016 0.25
N/20D2 RT009-like d11 1 0.016 0.032 Z32 (R) Z32 (R) 0.25 0.064 Z32 (R) o0.002 0.032 o0.016 0.032 0.125
N/20D3 RT009-like d12 1 0.125 0.25 Z32 (R) Z32 (R) 0.125 0.064 1 o0.002 0.064 o0.016 o0.016 0.125
Q/03D1 RT106 d01 0.25 0.064 0.064 Z32 (R) Z32 (R) 0.125 0.032 Z32 (R) o0.002 0.032 o0.016 o0.016 0.125
Q/03D2 RT106 d02 0.25 0.064 0.25 Z32 (R) Z32 (R) 0.125 0.032 2 (R) o0.002 0.064 0.032 0.032 0.25
Q/03D3 RT106 d01 0.25 0.125 0.125 Z32 (R) Z32 (R) 0.25 0.032 2 (R) o0.002 0.064 0.064 o0.016 0.25
a Isolates were retrieved from the same animal (B/08D1, B/08D2 and B/08D3; see Table 3).
b Toxin profiles: RT009-like, A-B-CDT- (but with a positive PCR result for tcdB); RT106, AþBþCDT-; RT154, AþBþCDT-; RT? (unknown ribotype), A-B-CDT-.
c According to the UPGMA dendrogram shown in Fig. 2 of Álvarez-Pérez et al. [1].
d Minimum inhibitory concentration (MIC). AMC, amoxicillin/clavulanic acid; CLI, clindamycin; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MTZ,














S. Álvarez-Pérez et al. / Data in Brief 14 (2017) 88–100100were always handled by experienced veterinary practitioners in strict accordance with good animal
practice and the Spanish legislation.
The owners of animals yielding a positive culture for C. difficile and/or C. perfringens were invited
to participate in a follow-up survey performed four months after the first study (in March 2016). In
this case, fecal swab samples and clinical information of animals was obtained as explained above.
The microbiology procedures used for C. perfringens and C. difficile isolation from fecal samples,
and the methods used for toxin profiling, PCR ribotyping, AFLP subtyping and in vitro antimicrobial
susceptibility testing of recovered isolates are detailed in our previous publication [1].Funding sources
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